MNG1024
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.507
- TGF_BETA_SIGNALING+0.449
- NOTCH_SIGNALING+0.387
- HEME_METABOLISM+0.305
- ADIPOGENESIS+0.281
- MITOTIC_SPINDLE+0.269
- PI3K_AKT_MTOR_SIGNALING+0.251
- ANDROGEN_RESPONSE+0.238
- FATTY_ACID_METABOLISM+0.226
- DNA_REPAIR+0.206
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.417
- ALLOGRAFT_REJECTION-0.384
- ANGIOGENESIS-0.338
- MYC_TARGETS_V2-0.305
- IL6_JAK_STAT3_SIGNALING-0.304
- INFLAMMATORY_RESPONSE-0.269
- INTERFERON_GAMMA_RESPONSE-0.263
- TNFA_SIGNALING_VIA_NFKB-0.260
- E2F_TARGETS-0.255
- PANCREAS_BETA_CELLS-0.247
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1007 | — | — | 0.886 |
| 2 | MNG1056 | — | — | 0.844 |
| 3 | TCGA-44-6146-01A-11R-A278-07 | — | cohortA1 | 0.814 |
| 4 | MNG1209 | — | — | 0.813 |
| 5 | MNG677 | — | — | 0.812 |
| 6 | TCGA-BH-A0BS-01A-11R-A12P-07 | — | B | 0.810 |
| 7 | MNG1043 | — | — | 0.808 |
| 8 | MNG1034 | — | — | 0.802 |
| 9 | TCGA-50-5932-01A-11R-1755-07 | — | cohortA2 | 0.800 |
| 10 | MNG1051 | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.507 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.449 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.387 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.305 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.281 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.269 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.251 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.238 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.226 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.206 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.206 | Inavolisib | — uncovered |
| PEROXISOME | 0.204 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.176 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.151 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.135 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.115 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.087 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.087 | Inavolisib | — uncovered |